ANTHEM BIOSCIENCES
|
ANTHEM BIOSCIENCES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 10.54 | 8.07 | 6.57 | 6.75 | 462.10 |
| CEPS(Rs) | 12.92 | 9.67 | 8.03 | 7.87 | 8.12 |
| DPS(Rs) | 2.00 | - | - | - | - |
| Book NAV/Share(Rs) | 53.57 | 42.49 | 34.43 | 30.51 | 1,543.98 |
| Tax Rate(%) | 28.20 | 31.30 | 23.05 | 22.54 | 25.74 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 38.20 | 36.26 | 35.59 | 40.01 | 46.06 |
| EBIT Margin(%) | 38.08 | 36.06 | 34.31 | 47.88 | 45.35 |
| Pre Tax Margin(%) | 37.76 | 35.49 | 33.63 | 47.05 | 44.36 |
| PAT Margin (%) | 27.11 | 24.38 | 25.88 | 36.44 | 32.94 |
| Cash Profit Margin (%) | 33.25 | 29.21 | 31.64 | 42.47 | 37.63 |
| Performance Ratios | |||||
| ROA(%) | 18.06 | 16.64 | 16.04 | 20.11 | 28.79 |
| ROE(%) | 21.98 | 20.99 | 20.04 | 24.89 | 39.44 |
| ROCE(%) | 29.62 | 28.55 | 24.21 | 31.08 | 50.94 |
| Asset Turnover(x) | 0.67 | 0.68 | 0.62 | 0.55 | 0.87 |
| Sales/Fixed Asset(x) | 1.56 | 1.61 | 1.51 | 1.33 | 1.78 |
| Working Capital/Sales(x) | 1.48 | 1.59 | 1.24 | 0.91 | 1.42 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.64 | 0.62 | 0.66 | 0.75 | 0.56 |
| Receivable days | 87.02 | 92.78 | 98.30 | 103.65 | 86.09 |
| Inventory Days | 38.87 | 54.41 | 43.81 | 32.40 | 13.83 |
| Payable days | 41.63 | 51.72 | 52.56 | 73.58 | 63.27 |
| Valuation Parameters | |||||
| PER(x) | 62.29 | - | - | - | - |
| PCE(x) | 50.79 | - | - | - | - |
| Price/Book(x) | 12.25 | - | - | - | - |
| Yield(%) | 0.30 | - | - | - | - |
| EV/Net Sales(x) | 17.25 | 0.03 | 0.11 | -0.10 | -0.25 |
| EV/Core EBITDA(x) | 37.02 | 0.06 | 0.28 | -0.20 | -0.49 |
| EV/EBIT(x) | 44.08 | 0.07 | 0.33 | -0.20 | -0.55 |
| EV/CE(x) | 11.84 | 0.02 | 0.07 | -0.06 | -0.22 |
| M Cap / Sales | 17.35 | - | - | - | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | 15.17 | 29.96 | 34.29 | -14.16 | 11.60 |
| Core EBITDA Growth(%) | 30.79 | 33.05 | 11.99 | -17.56 | 38.47 |
| EBIT Growth(%) | 24.56 | 37.05 | -3.76 | -9.37 | 45.96 |
| PAT Growth(%) | 31.14 | 22.86 | -4.64 | -5.02 | 49.48 |
| EPS Growth(%) | 30.53 | 22.86 | -2.69 | -98.54 | 44.52 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.02 | 0.05 | 0.12 | 0.07 | 0.03 |
| Current Ratio(x) | 3.79 | 3.39 | 3.49 | 5.16 | 3.48 |
| Quick Ratio(x) | 3.55 | 2.69 | 3.03 | 4.69 | 3.32 |
| Interest Cover(x) | 117.83 | 63.40 | 50.43 | 58.01 | 45.81 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of ANTHEM BIOSCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ANTHEM BIOSCIENCES | ₹52,784.9 Cr | -0.3% | 10.4% | 33.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹451,291.0 Cr | -1.8% | 7.6% | 11.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹305,014.0 Cr | 3.7% | 27.2% | 71.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹177,333.0 Cr | -2.3% | 1.5% | 23.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹115,017.0 Cr | 0.6% | 13.4% | 15.7% | Stock Analytics | |
| CIPLA | ₹112,539.0 Cr | -1.3% | 6.1% | -6.9% | Stock Analytics | |
ANTHEM BIOSCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ANTHEM BIOSCIENCES | -0.3% |
10.4% |
33.1% |
| SENSEX | 0.7% |
11.7% |
-2% |
You may also like the below Video Courses
